M

Mega Lifesciences PCL
SET:MEGA

Watchlist Manager
Mega Lifesciences PCL
SET:MEGA
Watchlist
Price: 26.75 THB 0.94%
Market Cap: 23.3B THB
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one MEGA stock under the Base Case scenario is 43.63 THB. Compared to the current market price of 26.75 THB, Mega Lifesciences PCL is Undervalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MEGA Relative Value
Base Case
43.63 THB
Undervaluation 39%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
95
vs Industry
54
Median 3Y
2.3
Median 5Y
2.4
Industry
2.5
Forward
1.6
More Details
11.8
P/E
P/E
Price to Earnings
11.8
vs History
95
vs Industry
32
Median 3Y
17.3
Median 5Y
18.5
Industry
21.2
Forward
10.5
More Details
10.4
P/OCF
P/OCF
Price to OCF
10.4
vs History
95
vs Industry
33
Median 3Y
17.1
Median 5Y
16.7
Industry
16.3
More Details
12.6
P/FCFE
P/FCFE
Price to FCFE
12.6
vs History
92
vs Industry
28
Median 3Y
19.8
Median 5Y
23.3
Industry
23.8
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
95
vs Industry
26
Median 3Y
3.8
Median 5Y
4.3
Industry
2.1
More Details
1.3
EV/S
EV/S
Enterprise Value to Sales
1.3
vs History
96
vs Industry
57
Median 3Y
2.1
Median 5Y
2.3
Industry
2.6
Forward
1.4
More Details
2.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.6
vs History
96
vs Industry
58
Median 3Y
4.6
Median 5Y
5.5
Industry
5.2
More Details
5.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.5
vs History
96
vs Industry
41
Median 3Y
10.5
Median 5Y
13.3
Industry
12.5
Forward
6.5
More Details
6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
6
vs History
96
vs Industry
42
Median 3Y
11.5
Median 5Y
14.7
Industry
15.9
Forward
7.4
More Details
8.8
EV/OCF
EV/OCF
Enterprise Value to OCF
8.8
vs History
96
vs Industry
38
Median 3Y
15.8
Median 5Y
15.9
Industry
14.6
More Details
11.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
11.3
vs History
96
vs Industry
30
Median 3Y
18
Median 5Y
18.2
Industry
17.2
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
96
vs Industry
26
Median 3Y
3.6
Median 5Y
3.7
Industry
1.8
More Details

Multiples Across Competitors

MEGA Competitors Multiples
Mega Lifesciences PCL Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
TH
Mega Lifesciences PCL
SET:MEGA
23.3B THB 1.6 11.8 5.5 6
US
Eli Lilly and Co
NYSE:LLY
736.4B USD 15 66.4 35.6 38.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
374.9B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.5 12.8 14.7
CH
Roche Holding AG
SIX:ROG
204.7B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
190.2B CHF 4.5 18.7 11 14.7
UK
AstraZeneca PLC
LSE:AZN
158.4B GBP 3.9 27.9 130.6 197
US
Merck & Co Inc
NYSE:MRK
204.7B USD 3.2 11.8 8.7 10.6
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
144.4B USD 2.3 18.4 7.8 10.9
P/E Multiple
Earnings Growth PEG
TH
M
Mega Lifesciences PCL
SET:MEGA
Average P/E: 23.9
11.8
9%
1.3
US
Eli Lilly and Co
NYSE:LLY
66.4
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.5
18%
1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
18.7
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
27.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.8
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.4
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
TH
M
Mega Lifesciences PCL
SET:MEGA
Average EV/EBITDA: 394.7
5.5
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
35.6
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
11
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.6
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
TH
M
Mega Lifesciences PCL
SET:MEGA
Average EV/EBIT: 1 698
6
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
38.9
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.7
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.6
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1

See Also

Summary
MEGA intrinsic value, competitors valuation, and company profile.
DCF Valuation
MEGA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MEGA stock valuation using valuation multiples.
Wall Street Estimates
MEGA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MEGA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 265,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.